DrugDashboards

Progesterone

Progesterone · PROGESTERONE 100 mg/1 · Capsule · Oral · Redpharm Drug

NDC 67296-2283-09 · 90 CAPSULE in 1 BOTTLE · ANDA · View full market →

The short version

14 companies list this market (plus 15 repackagers, which add no supply) — deep enough that no single failure threatens the supply.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

ⓘ How this was built
Data sources
  • FDA NDC Directory (openFDA) — labelers active in the last 30 days, repackagers classified from DailyMed SPL establishment roles
  • CMS NADAC — latest price vs the price in effect ~12 months earlier
  • FDA drug shortages and enforcement reports (openFDA)
  • FDA inspection classifications; DrugDashboards fragility score and 90-day shortage model
Method

Each sentence is a template that fires only when its condition holds in the data shown lower on this page: maker counts are distinct FDA labelers listing this molecule and dosage form in the last 30 days minus classified repackagers; the price trend compares the newest NADAC with the last price in effect at least 9 months earlier; shortage and recall sentences restate FDA rows for this drug's presentations (Class I/II, trailing 12 months); the plant sentence needs a MANUFACTURE-role establishment with a drug-quality OAI in 24 months; the verdict restates the fragility band; the risk sentence appears only when the model's probability is at least 1.5× the typical market. Nothing here is inferred beyond those rules.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 70700-0162-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$0.4005per unit
middle half $0.3209–$0.6402 · 5,237 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $0.4005
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
95%of plans cover it
tier 2 · prior auth 0% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies a 25–40% brand range derived from MedPAC's program-wide aggregates to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

ⓘ How this was built
Data sources
  • CMS NADAC weekly files (data.medicaid.gov), December 2024 onward
  • CMS NADAC per-year archive files, 2013 – November 2024, averaged per month
  • CMS Federal Upper Limit file — weighted average manufacturer price (WAMP) of the generic group (dashed line)
Method

One line, two regimes: before December 2024 each point is the average of that month's archived NADAC rows for this NDC; from December 2024 each point is a row from the weekly file, which CMS publishes only when the price changes, so the line holds flat until the next change and is extended to today when the last row is under 6 months old. Since the December 2024 file CMS computes generic NADAC as a 3-month moving average, so recent generic moves are smoothed and lag the market. The dashed WAMP is the manufacturer-side average for the whole multiple-source group, not this NDC alone. To check a point: open the NADAC file for that date on data.medicaid.gov and find this NDC.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NDCs that have a NADAC price and a generic name.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for progesterone (oral solid) in the next 90 days

For scale: the typical drug’s chance is about 0.1% — this one is less than 1.5× that, which we treat as ordinary.

Backtested statistical model over the whole market, not this package alone. Model details →

ⓘ How this was built
Data sources
  • FDA NDC Directory labeler counts, CMS NADAC price trend, openFDA shortages and enforcement, FDA inspection classifications, Wayback archive of FDA's shortage list (labels)
Method

A logistic regression over molecule × dosage-form markets, trained on a monthly grid of historical dates since 2019 with labels equal to whether a new FDA shortage posting appeared within the following 90 days; eight features knowable on each date (labeler count, sole-source flag, NADAC year-over-year change, Class I/II recalls, injectable form, discontinuation filings, open shortage episodes, recent OAI inspection). The probability shown is the model's output for today's feature values; the reasons are the features pushing this market's probability up, listed only when the feature actually holds here. Held-out performance and coefficients are on the fragility page.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Regulatory

Application
ANDA205229
TE code
AB
Approval date
Oct 20, 2017
Patents / exclusivity
None on file
ⓘ How this was built
Data sources
  • FDA Orange Book data files — patent and exclusivity tables for application ANDA205229, edition retrieved 2026-08-24
Method

Rows are the Orange Book's patent and exclusivity listings for this NDA, de-duplicated across product numbers (the file repeats a listing for every strength). A listed patent is a claim the sponsor filed; it may cover a use rather than the molecule, may be challenged, and may be delisted — a listing is not proof a generic is blocked. Pediatric extensions appear as *PED rows. FDA blocks automated downloads of the Orange Book from cloud servers, so the edition can trail FDA's monthly release; the retrieval date above is the edition shown. To check: search the application number on FDA's Orange Book site.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Shortage history

ⓘ How this was built
Data sources
  • FDA drug shortages via openFDA (current file: Current, To Be Discontinued, and recently Resolved rows)
  • Internet Archive (Wayback) snapshots of FDA's shortage list since 2019, reconstructed into episodes
  • DrugDashboards Kaplan–Meier duration curves and conditional duration model
Method

Top rows are FDA's live listings whose package NDC is this product or another package of the same generic name and dosage form. openFDA drops resolved rows after about six months, so older episodes come from monthly Wayback snapshots of FDA's file, matched on the molecule with dosage-form words stripped (that matching can pull in other salts or forms of the same molecule — the presentation is shown so you can tell). 'Month N of a typical M' compares this episode's age with the Kaplan–Meier median for its form class (injectable, oral solid, other) over episodes since October 2019, open episodes censored; the resolution odds come from a model conditioned on the episode's age and reason. To check: FDA's drug shortage database, and web.archive.org for its history.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Not on FDA's current shortage list. Archived episodes below.

Archived episodes (FDA list history via Wayback, 2019+)
  • Planned discontinuation — AbbVie Inc., Crinone, Vaginal Gel, 4% (NDC 0023-6150-04) (listed as “Progesterone Vaginal Gel”)Mar 27, 2026 → last seen Jul 20, 2026
  • Shortage ended — Teva Pharmaceuticals, 50MG 1X10ML (NDC 0591-3128-79) (listed as “Progesterone Injection, USP”)Dec 21, 2017 → Sep 23, 2019
  • Shortage ended — Fresenius Kabi USA, LLC, 500 mg per 10 mL, MDV (NDC 63323-0261-10) (listed as “Progesterone Injection, USP”)Dec 21, 2017 → Sep 23, 2019
  • Shortage ended — Hikma Pharmaceuticals USA, Inc. (formerly West-Ward), 50 mg/mL, 10 mL (NDC 0143-9725-01) (listed as “Progesterone Injection, USP”)Dec 21, 2017 → Sep 23, 2019
  • Shortage ended — AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.), 500 mg/10 mL multiple dose vial (NDC 55150-306-10) (listed as “Progesterone Injection, USP”)Dec 21, 2017 → Sep 23, 2019

Recalls (this NDC)

ⓘ How this was built
Data sources
  • FDA drug enforcement reports via openFDA
Method

Enforcement reports whose product NDC list includes this exact package NDC, newest first, with FDA's classification (I = reasonable probability of serious harm, II = temporary or reversible harm, III = unlikely to cause harm) and the recall's current status. Reports for other packages of the same drug are not shown here; 275 of the last year's Class I/II reports carry no NDC at all and cannot be matched. To check: search the recall number on openFDA or FDA's enforcement reports.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

No enforcement reports list this package NDC.

Labelers of Progesterone (Capsule)

29 labelers active in the last 30 days, of which 15 are repackagers; 0not seen for 30+ days. Keyed on FDA's generic-name string — other salts or forms of the molecule are separate rosters.

ⓘ How this was built
Data sources
  • FDA NDC Directory (openFDA), read daily since 2026-07-15 — labeler_name per package
  • DailyMed SPL establishment roles + name patterns → derived.labeler_kinds (repackager / manufacturer / unknown)
Method

One row per labeler that lists any package with this exact generic-name string and dosage form; strengths are combined. 'First seen' is the first daily snapshot that contained the labeler here (2026-07-15 for everything present at the start), 'last seen' the most recent; a labeler counts as active when seen in the last 30 days. Repackagers and relabelers are flagged when their own labels show only repack/relabel operations or their name matches a known repackager, and are excluded from every 'makers' count on this page. Listing is not volume: a labeler with a listed NDC may ship little or nothing. To check: search the generic name in FDA's NDC Directory and list the labelers.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

LabelerStrengthsFirst seenLast seen
A-S Medication SolutionsrepackagerPROGESTERONE 100 mg/1Jul 15, 2026Sep 3, 2026
Asclemed USA, Inc.repackagerPROGESTERONE 200 mg/1; PROGESTERONE 100 mg/1Jul 15, 2026Sep 3, 2026
AvKARErepackagerPROGESTERONE 200 mg/1; PROGESTERONE 100 mg/1Jul 15, 2026Sep 3, 2026
Bryant Ranch PrepackrepackagerPROGESTERONE 200 mg/1; PROGESTERONE 100 mg/1Jul 15, 2026Sep 3, 2026
Catalent Pharma Solutions, LLCPROGESTERONE 100 mg/1; PROGESTERONE 200 mg/1Jul 15, 2026Sep 3, 2026
Preferred Pharmaceuticals Inc.repackagerPROGESTERONE 100 mg/1; PROGESTERONE 200 mg/1Jul 15, 2026Sep 3, 2026
Proficient Rx LPrepackagerPROGESTERONE 100 mg/1; PROGESTERONE 200 mg/1Jul 15, 2026Sep 3, 2026
Remedyrepack Inc.repackagerPROGESTERONE 100 mg/1Jul 15, 2026Sep 3, 2026
Acertis Pharmaceuticals, LLCPROGESTERONE 100 mg/1; PROGESTERONE 200 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCPROGESTERONE 100 mg/1; PROGESTERONE 200 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedPROGESTERONE 100 mg/1; PROGESTERONE 200 mg/1Jul 15, 2026Sep 2, 2026
Catalent Pharma Solutions LLCPROGESTERONE 400 mg/1Jul 15, 2026Sep 2, 2026
direct rxrepackagerPROGESTERONE 100 mg/1; PROGESTERONE 200 mg/1Jul 15, 2026Sep 2, 2026
Direct RxrepackagerPROGESTERONE 200 mg/1Jul 15, 2026Sep 2, 2026
Direct_RxrepackagerPROGESTERONE 100 mg/1Jul 15, 2026Sep 2, 2026
Dr. Reddy's Laboratories Inc.PROGESTERONE 100 mg/1; PROGESTERONE 200 mg/1Jul 15, 2026Sep 2, 2026
Dr. Reddys Laboratories, Inc.PROGESTERONE 100 mg/1; PROGESTERONE 200 mg/1Jul 15, 2026Sep 2, 2026
Golden State Medical Supply, Inc.repackagerPROGESTERONE 100 mg/1; PROGESTERONE 200 mg/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA IncPROGESTERONE 100 mg/1; PROGESTERONE 200 mg/1Jul 15, 2026Sep 2, 2026
Northstar Rx LLCPROGESTERONE 100 mg/1; PROGESTERONE 200 mg/1Jul 15, 2026Sep 2, 2026
NorthStar Rx LLCPROGESTERONE 100 mg/1; PROGESTERONE 200 mg/1Aug 5, 2026Sep 2, 2026
Northwind Health Company, LLCrepackagerPROGESTERONE 100 mg/1Jul 15, 2026Sep 2, 2026
NuCare Pharmaceuticals, Inc.repackagerPROGESTERONE 100 mg/1Jul 15, 2026Sep 2, 2026
NuCare Pharmaceuticals,Inc.repackagerPROGESTERONE 100 mg/1; PROGESTERONE 200 mg/1Jul 15, 2026Sep 2, 2026
Patheon Softgels Inc.PROGESTERONE 100 mg/1; PROGESTERONE 200 mg/1Jul 15, 2026Sep 2, 2026
Patheon Softgels, Inc.PROGESTERONE 100 mg/1; PROGESTERONE 200 mg/1Jul 15, 2026Sep 2, 2026
Xiromed, LLCPROGESTERONE 100 mg/1; PROGESTERONE 200 mg/1Jul 15, 2026Sep 2, 2026
Bionpharma Inc.PROGESTERONE 100 mg/1; PROGESTERONE 200 mg/1Jul 15, 2026Aug 31, 2026
Redpharm DrugrepackagerPROGESTERONE 100 mg/1Jul 25, 2026Aug 29, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 15, 2026.

Cite this page

DrugDashboards, "Progesterone — NDC 67296-2283-09," retrieved September 4, 2026, https://drugdashboards.com/drug/67296228309.

Free to cite with attribution — see how the data is put together.